The drug generated $4.4 billion in the first 9 months of 2024, but BMS expects an "additional step down” to $2 billion to $2.5 billion in 2025. In addition, Pomalyst and Sprycel are expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback